Antiarrhythmic Agents
Antiarrhythmic Agents - Related Videos
01:24
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
0 Views •
2024
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:22
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
0 Views •
2024
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart. Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
0 Views •
2024
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
0 Views •
2024
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation. Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
11:27
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
0 Views •
Cited by 5 •
2016
This protocol describes the preparation and characterization of a dendrimeric magnetic resonance imaging (MRI) contrast agent that carries cyclen-based macrocyclic chelates coordinating paramagnetic gadolinium ions. In a series of MRI experiments in vitro, this agent produced an amplified MRI signal when compared to the commercially available monomeric analogue.
FAQs
Class-specific effects determine which part of cardiac electrical activity changes. Sodium-channel blockers relate to excitability and impulse conduction, while potassium-channel blockers influence action-potential duration and refractoriness. Beta-adrenergic antagonists act through autonomic signaling, and calcium-channel blockers affect conduction pathways. Comparing these effects helps match pharmacologic action to the rhythm being treated.
These properties represent distinct aspects of cardiac electrical behavior. A drug may alter action-potential duration, reduce tissue excitability, slow impulse transmission, or extend the period during which tissue cannot be reactivated. Distinguishing these outcomes clarifies why agents with different channel or receptor targets can produce different effects on abnormal cardiac rhythms.
The therapeutic benefit of antiarrhythmic agents is inseparable from their potential to provoke new rhythm disturbances. Modifying ion channels, autonomic receptors, or conduction pathways can correct abnormal electrical activity, but the same alteration may destabilize cardiac signaling under some circumstances. This risk makes underlying cardiac condition and adverse-effect potential central to pharmacologic evaluation.
Selection begins with the arrhythmia, then incorporates the patient's underlying cardiac condition and the adverse effects associated with available mechanisms. Pharmacologists can compare whether sodium-channel, beta-adrenergic, potassium-channel, or calcium-channel actions best address the electrical abnormality. This individualized reasoning supports safer use rather than treating all rhythm disorders with one pharmacologic strategy.
Clinical application spans several rhythm problems, including atrial fibrillation, supraventricular tachycardia, and ventricular arrhythmias. The relevant choice depends on how the abnormal rhythm relates to cardiac electrical activity and on the patient's broader cardiac condition. Studying these applications shows why treatment decisions require both rhythm-focused reasoning and attention to safety.
In pharmacology, antiarrhythmic agents provide a framework for connecting molecular targets with whole-heart outcomes. Investigators can examine how ion-channel modulation, autonomic receptor effects, or altered conduction pathways translate into changes in excitability, impulse transmission, action-potential duration, and refractoriness. This perspective helps explain both rhythm control and the possibility of adverse electrical effects.